Role of microvesicles as biomarkers and future pharmacology targets of cardiovascular diseases
In the 1990´s, it was discovered a new cell-cell communication system based on the action of vesicles that cargo bioactive molecules, on neighboring cells. These vesicles, known as extracellular vesicles (EVs) act as regulators of several physiological processes but also participate in the developme...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2018 |
| País: | España |
| Institución: | Universidad de Alcalá (UAH) |
| Repositorio: | e_Buah Biblioteca Digital Universidad de Alcalá |
| Idioma: | español |
| OAI Identifier: | oai:ebuah.uah.es:10017/64783 |
| Acceso en línea: | http://hdl.handle.net/10017/64783 |
| Access Level: | acceso abierto |
| Palabra clave: | Farmacia Pharmacy |
| Sumario: | In the 1990´s, it was discovered a new cell-cell communication system based on the action of vesicles that cargo bioactive molecules, on neighboring cells. These vesicles, known as extracellular vesicles (EVs) act as regulators of several physiological processes but also participate in the development and progression of multiple diseases. Microvesicles (MVs) are types of EVs that are implicated in the etiopathogenesis of a large number of cardiovascular diseases due to they take part in the onset of atherosclerosis. Different cardioprotective drugs have shown to have an effect on MVs. In addition, since the discovery that MVs are capable of transferring biological information, the use of them as drug delivery vehicles has gained scientific interest. The aim of this work is to analyze the involvement of MVs in the origin of atherosclerosis to demonstrate their role as diagnostic biomarkers, as well as to review the pharmacological effect of current therapies on MVs and their role as therapeutic tool. |
|---|